Q2 2026 Management View CEO Kim Kelderman reported that "our second quarter performance was largely in line with our expectations. Continued strength from our large pharma customers was offset by a ...

Life sciences company Bio-Techne (NASDAQ:TECH) reported Q4 CY2025 results , but sales were flat year on year at $295.9 million. Its non-GAAP profit of $0.46 per share was 5.8% above analysts’ ...

Bio-Techne tops Q2 EPS and revenue estimates as operating margin jumps 244 bps, even with flat organic sales and a slight year-over-year revenue dip.

Life sciences company Bio-Techne (NASDAQ:TECH) will be announcing earnings results this Wednesday before market open. Here’s ...

Bio-Techne (NASDAQ: TECH) just disclosed its Q2 earnings on Wednesday, February 4, 2026 at 06:30 AM. Here's a brief overview ...

Q2 2026 Earnings Call February 4, 2026 9:00 AM ESTCompany ParticipantsDavid Clair - VP of Investor Relations & ...

Earlier in 2026, Bio-Techne highlighted its leadership in spatial biology and proteomic analysis under new CEO Kim Kelderman, ...

MINNEAPOLIS - Bio-Techne Corporation (NASDAQ:TECH) reported flat revenue but improved profitability in its second quarter fiscal 2026 results, with adjusted earnings per share rising to $0.46 compared ...

Aristotle Atlantic Partners, LLC, an investment advisor, released its “Large Cap Growth Strategy” second quarter 2025 investor letter. A copy of the letter can be downloaded here. The US equity market ...

Shares of Bio-Techne Corp. TECH slid 2.41% to $63.98 Thursday, on what proved to be an all-around mixed trading session for ...

Combines chemiluminescence detection with dual-channel fluorescence in the near-infrared and infrared (NIR and IR) ranges for expanded multiplexing Enables up to 24 targets per sample and supports ...

Bio-Techne Corp. closed 11.77% below its 52-week high of $75.69, which the company achieved on February 7th.